Printer Friendly

NYCOMED BECOMES NEW ASSOCIATE FOR FOUNTAIN PHARMACEUTICALS IN EUROPE

 LARGO, Fla., Dec. 9 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI) announced today it has entered into a licensing and supply agreement with Nycomed Dak, a major Danish company with pharmaceutical sales in excess of $400 million.
 The arrangement encompasses the Scandinavian markets and the parties plan to discuss additional markets and products over the next several months. Initial orders, estimated at approximately $100,000, will be shipped in the first quarter of 1994.
 "We are very pleased that a company of Nycomed's stature will be marketing our line," said John C. Walsh, Fountain's president and CEO. The association with Nycomed, together with existing relationships with Spirig A.G. and Yamanouchi's Brocades organization, positions the company very well in Europe and beyond, according to Walsh.
 Based in Largo, Fountain Pharmaceuticals is a publicly traded company that specializes in the application of encapsulated drug delivery systems for the pharmaceutical and cosmetic industries. The company's shares are traded in the NASDAQ small caps grouping.
 /delval/
 -0- 12/6/93
 /CONTACT: John C. Walsh, president and CEO of Fountain Pharmaceuticals, 813-392-5300/
 (FPHI)


CO: Fountain Pharmaceuticals, Inc.; Nycomed Dak ST: Florida IN: MTC SU: LIC

JO-MK -- PH018 -- 2261 12/09/93 13:55 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1993
Words:199
Previous Article:BOARD OF DIRECTORS OF THE NOSTALGIA NETWORK, INC. RECOMMENDS THAT SHAREHOLDERS DECLINE TENDER OFFER
Next Article:MASLAND INDUSTRIES NAMES NEW BOARD MEMBERS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters